Advertise on podcast: Pharmacology News

Two people may take medications that influence the same neurotransmitter systems, yet their psychological and behavioral experiences can be remarkably different. Why do some individuals develop compulsive stimulant use while others experience improved attention, emotional regulation, and everyday functioning? This episode explores the psychology of addiction, reward learning, impulsivity, reinforcement, and the relationship between ADHD and substance use disorders. We also examine how expectations, environmental influences, psychiatric vulnerabilities, and patterns of drug exposure help explain why stimulant use does not inevitably lead to addiction.

Explore how amphetamine-based medications influence dopamine and norepinephrine signaling, why subjective concentration can differ from measurable cognitive improvement, and how dose and sleep deprivation influence outcomes.

Explore the psychological and clinical challenges of distinguishing antidepressant discontinuation symptoms from the return of depression or anxiety. Examine how symptom timing, physical sensations, and emotional changes influence clinical assessment, and why a careful medication history is essential.

What happens when a facility entrusted with treating substance-use disorders allegedly helps perpetuate the very addiction it promises to address? This episode examines the neurobiology of opioid and stimulant dependence, withdrawal, craving, and the medications used in evidence-based addiction treatment. We explore how access to drugs, inadequate medical supervision, and repeated treatment disruptions can undermine recovery. The Southern California rehab fraud allegations provide a disturbing backdrop for understanding the difference between legitimate pharmacological treatment and exploiting addiction for financial gain.

Not every SSRI is interchangeable — choosing the right one depends on far more than just the diagnosis in front of you. This episode compares seven SSRIs across their FDA-approved indications for depression, OCD, panic disorder, and generalized anxiety disorder, breaking down half-lives, side-effect profiles, and the prescribing nuances that separate one agent from another. We cover pediatric and geriatric precautions, key drug interactions, discontinuation syndrome, and the risk of serotonin toxicity. Built for PMHNP board prep, this episode walks through how to distinguish these medications in real clinical scenarios and match treatment to patient presentation.

Antipsychotic medications frequently act on dopamine D2 receptors, but blocking these receptors produces different effects depending on where they are located in the brain. This episode examines how dopamine antagonism and partial agonism influence psychotic symptoms, movement disorders, and prolactin secretion. We compare first-generation and second-generation antipsychotics, including haloperidol, risperidone, aripiprazole, and clozapine. The discussion explains why understanding receptor pharmacology is essential for balancing therapeutic benefits against adverse effects.

Explore pharmacokinetics, CYP450 metabolism, serotonin transporter inhibition, and receptor adaptations. Explain why medications within the same class can differ in tolerability and interaction potential.

Explore serotonin transporters, receptor adaptations, and the differences between immediate medication effects and delayed clinical improvement. Explain why antidepressant response cannot be reduced to a simple chemical imbalance.

Methamphetamine and prescription amphetamines share important pharmacological properties, but differences in chemical structure, dosing, delivery, and medical supervision can profoundly affect their risks. This episode compares methamphetamine, Adderall, and Ritalin through the lens of neurotransmitter activity and clinical pharmacology. We also explore why methamphetamine itself retains a limited legitimate medical role despite its association with severe addiction.

Explore serotonin transporters, receptor adaptations, and the differences between immediate medication effects and delayed clinical improvement. Explain why antidepressant response cannot be reduced to a simple chemical imbalance.

A new class of synthetic opioids known as orphine analogues has been detected in illicit drug supplies across 22 American states, raising concerns about the next evolution of the opioid crisis. Some of these compounds have demonstrated pharmacological potency substantially greater than fentanyl, while conventional drug screening methods may fail to identify them. We examine how these substances affect the brain, why respiratory depression is so dangerous, and what makes their detection and treatment particularly challenging. We also explore the implications for emergency medicine, forensic toxicology, and the future of opioid pharmacology.

Antidepressants influence neurotransmission relatively quickly, yet meaningful clinical improvement often takes longer. This episode explores receptor signaling, neural adaptation, stress circuitry, and neuroplasticity in depression treatment. Discover why changes in brain function are more complicated than the familiar chemical-imbalance explanation.

Hallucinations, paranoia, agitation, and bizarre behavior can reasonably lead clinicians toward antipsychotic treatment, but what happens when the underlying illness isn’t primarily psychiatric? Anti-NMDA receptor encephalitis can initially resemble a severe psychiatric disorder before neurological symptoms emerge. This episode examines the diagnostic clues that can change the entire treatment strategy.

SSRIs begin altering serotonin signaling within hours, yet people with depression or anxiety are often told that meaningful improvement may take weeks. Why does the brain respond so slowly if the medication begins working almost immediately? The answer reveals why the familiar idea of antidepressants simply “correcting a chemical imbalance” is far too simplistic. This episode explores serotonin transporters, receptor adaptation, neural plasticity, and the gradual biological changes that may contribute to antidepressant effects. It also explains why an SSRI can be pharmacologically active long before a person notices a meaningful psychological difference.

A new study published in The American Journal of Psychiatry analyzed electronic health records from 2,086 individuals with bipolar disorder in Hong Kong treated between 2004 and 2023. While long-acting injectable antipsychotics (LAIAs) are already widely recognized for treating schizophrenia, robust comparative guidance for bipolar disorder has historically been limited. The researchers found that patients receiving LAIAs had a significantly lower risk of psychiatric hospitalization compared to those on traditional oral antipsychotics. In addition, the injectable treatments were tied to a reduced recurrence rate of manic and mixed episodes, offering compelling evidence for their expanded clinical role.